Table 2.
Tumor-Associated Antigens Targeted in CAR-T Cell Therapy for Solid Tumors.
| Tumor Type | Target |
|---|---|
| Glioblastoma | Epidermal Growth Factor Receptor (EGFR) |
| Epidermal Growth Factor Receptor vIII (EGFRvIII) | |
| Interleukin-13 Receptor Alpha-2 (IL13Rα2) | |
| CD133 | |
| Neuroblastoma | Disialoganglioside GD2 (GD2) |
| L1 Cell Adhesion Molecule (L1-CAM) | |
| Lung Cancer | EGFR |
| Mesothelin (MSLN) | |
| Human Epidermal Growth Factor 2 (HER2) | |
| Breast Cancer | HER2 |
| MSLN | |
| Tyrosine-Protein Kinase Met (cMET) | |
| Gastric Cancer | Carcinoembryonic antigen (CEA) |
| HER2 | |
| Pancreatic Cancer | CEA |
| MSLN | |
| Renal Cell Carcinoma | Vascular Endothelial Growth Factor Receptor (VEGFR) |
| Carbonic anhydrase 9 (CAIX) | |
| Colon Cancer | HER2 |
| CEA | |
| Prostate Cancer | Prostate Membrane Antigen (PSMA) |
| Prostate Stem Cell Antigen (PSCA) | |
| Ovarian Cancer | Mucin 16(MUC-16)/CA-125 |
| HER2 | |
| MSLN | |
| L1-CAM | |
| Folate Receptor Alpha (FR-α) | |
| Cancer/Testis Antigen 1 (CTAG1B) | |
| Melanoma | GD2 |
| L1-CAM | |
| CTAG1B | |
| Osteosarcoma | GD2 |
| HER2 |